These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 24361678)

  • 1. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.
    Hraber P; Seaman MS; Bailer RT; Mascola JR; Montefiori DC; Korber BT
    AIDS; 2014 Jan; 28(2):163-9. PubMed ID: 24361678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments.
    Hraber P; Rademeyer C; Williamson C; Seaman MS; Gottardo R; Tang H; Greene K; Gao H; LaBranche C; Mascola JR; Morris L; Montefiori DC; Korber B
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28747500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.
    Sanchez-Merino V; Fabra-Garcia A; Gonzalez N; Nicolas D; Merino-Mansilla A; Manzardo C; Ambrosioni J; Schultz A; Meyerhans A; Mascola JR; Gatell JM; Alcami J; Miro JM; Yuste E
    J Virol; 2016 Jun; 90(11):5231-5245. PubMed ID: 26984721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies.
    deCamp A; Hraber P; Bailer RT; Seaman MS; Ochsenbauer C; Kappes J; Gottardo R; Edlefsen P; Self S; Tang H; Greene K; Gao H; Daniell X; Sarzotti-Kelsoe M; Gorny MK; Zolla-Pazner S; LaBranche CC; Mascola JR; Korber BT; Montefiori DC
    J Virol; 2014 Mar; 88(5):2489-507. PubMed ID: 24352443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broadly Neutralizing Antibody Responses in a Subset of HIV-1-Infected Individuals in Chennai, India.
    Hussain SI; Panneerselvam N; Solomon S; Solomon SS; Adam K; Chandrasekaran E; Montefiori DC; Pachamuthu B
    J Int Assoc Provid AIDS Care; 2017; 16(2):201-208. PubMed ID: 23422744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
    Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies.
    Hraber P; Korber BT; Lapedes AS; Bailer RT; Seaman MS; Gao H; Greene KM; McCutchan F; Williamson C; Kim JH; Tovanabutra S; Hahn BH; Swanstrom R; Thomson MM; Gao F; Harris L; Giorgi E; Hengartner N; Bhattacharya T; Mascola JR; Montefiori DC
    J Virol; 2014 Nov; 88(21):12623-43. PubMed ID: 25142591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
    Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum neutralizing activities from a Beijing homosexual male cohort infected with different subtypes of HIV-1 in China.
    Zhang M; Jiao Y; Wang S; Zhang L; Huang Z; Chen Y; Wu H
    PLoS One; 2012; 7(10):e47548. PubMed ID: 23094060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization breadth and potency of serum derived from recently human immunodeficiency virus type 1-infected Thai individuals.
    Chaitaveep N; Utachee P; Chuenchitra T; Karasavvan N; Takeda N; Kameoka M
    Microbes Infect; 2016 May; 18(5):346-53. PubMed ID: 26774333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants.
    Burton S; Spicer LM; Charles TP; Gangadhara S; Reddy PBJ; Styles TM; Velu V; Kasturi SP; Legere T; Hunter E; Pulendran B; Amara R; Hraber P; Derdeyn CA
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30651354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.
    Kong R; Louder MK; Wagh K; Bailer RT; deCamp A; Greene K; Gao H; Taft JD; Gazumyan A; Liu C; Nussenzweig MC; Korber B; Montefiori DC; Mascola JR
    J Virol; 2015 Mar; 89(5):2659-71. PubMed ID: 25520506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy.
    Hu X; Hong K; Zhao C; Zheng Y; Ma L; Ruan Y; Gao H; Greene K; Sarzotti-Kelsoe M; Montefiori DC; Shao Y
    J Gen Virol; 2012 Oct; 93(Pt 10):2267-2278. PubMed ID: 22791603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth.
    Chukwuma VU; Kose N; Sather DN; Sapparapu G; Falk R; King H; Singh V; Lampley R; Malherbe DC; Ditto NT; Sullivan JT; Barnes T; Doranz BJ; Labranche CC; Montefiori DC; Kalams SA; Haigwood NL; Crowe JE
    PLoS One; 2018; 13(12):e0209437. PubMed ID: 30566528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutralizing activity.
    van Gils MJ; Edo-Matas D; Schweighardt B; Wrin T; Schuitemaker H
    J Gen Virol; 2010 Jan; 91(Pt 1):250-8. PubMed ID: 19793903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycan-Dependent Neutralizing Antibodies Are Frequently Elicited in Individuals Chronically Infected with HIV-1 Clade B or C.
    Cohen YZ; Lavine CL; Miller CA; Garrity J; Carey BR; Seaman MS
    AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1192-201. PubMed ID: 26149894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRF01_AE-specific neutralizing activity observed in plasma derived from HIV-1-infected Thai patients residing in northern Thailand: comparison of neutralizing breadth and potency between plasma derived from rapid and slow progressors.
    Sapsutthipas S; Tsuchiya N; Pathipavanich P; Ariyoshi K; Sawanpanyalert P; Takeda N; Isarangkura-na-ayuthaya P; Kameoka M
    PLoS One; 2013; 8(1):e53920. PubMed ID: 23308290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross Type Neutralizing Antibodies Detected in a Unique HIV-2 Infected Individual From India.
    Vidyavijayan KK; Cheedarala N; Babu H; Precilla LK; Sathyamurthi P; Chandrasekaran P; Murugavel KG; Swaminathan S; Tripathy SP; Hanna LE
    Front Immunol; 2018; 9():2841. PubMed ID: 30619250
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.